Aditxt, Inc.

The company, incorporated in Delaware on September 28, 2017, and headquartered in Mountain View, California, focuses on redefining how health innovations are discovered, developed, and deployed. Its mission is to transform a centralized industry into a socially owned and guided ecosystem to advance human well-being by engaging stakeholders in all aspects of innovation. Initially, the company focused on an immune modulation technology called ADI/Adimune, aimed at prolonging and enhancing the life quality of organ transplant patients. Since then, it has expanded its portfolio of innovations and subsidiaries and continues to evaluate various promising health innovations. In January 2023, the subsidiary Adimune™, Inc. was formed to lead the company's immune modulation therapeutic programs. Adimune's proprietary product, Apoptotic DNA Immunotherapy™ (ADI™), uses a novel approach that mimics the body's natural tolerance induction to its own tissues. It consists of two DNA molecules designed to deliver signals to induce tolerance. ADI-100, the first product candidate from the ADI platform, is designed to tolerize against glutamic acid decarboxylase ("GAD"), an antigen implicated in type-1 diabetes (T1D), psoriasis, and many autoimmune diseases of the CNS. ADI-100 has been successfully tested in several preclinical models, including skin grafting, psoriasis, and T1D. All preclinical studies for ADI-100 are complete, providing data supporting its potential effectiveness in restoring durable tolerance, as shown in 10-month studies for preventing and treating T1D in nonclinical animal models.